Opus Genetics is trading at $3.95, down 7.49%, amid a broad November 5 sell-off in U.S. technology shares and major indexes.
- Reports cite renewed concerns about AI investment and data-center regulation.
- The company announced dosing completion for 11 participants in the higher-dose BIRD-1 Cohort 2; this update was not reported as an explanation for the decline.
- No clear company-specific negative catalyst was found. Topline data is expected in Q1 2027.